Aftab Ahmed Jalbani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aftab Ahmed Jalbani has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Muneera AlTaweel
King Abdulaziz Hospital, MNGHA
2 shared publications - Zafar Iqbal
Genomic & Experimental Medicine Group (GEM) & Quality Assurance and Accreditation Unit (QAAA), CLSP, College of Applied Medical Sciences (CoAMS-A, King Saud Bin Abdulaziz University for Health Sciences, Al-Ahsa, Saudi Arabia; Division of Adult Oncology, Department of Medicine, King Abdulaziz Hospital, Al-Ahsa, Saudi Arabia; Centers of Excellence in Precision Medicine, Oncology and Biotechnology, INNOVACORE Center for Research & Biotechnology, San Antonio, Texas, USA, Saudi Arabia
2 shared publications - Abdulkareem Al-Garni
Genomic & Experimental Medicine Group (GEM), Quality Assurance & Accreditation Unit (QAAA) and Clinical Laboratory Sciences Program (CLSP), College of Applied Medical Sciences (CoAMS-A) King Saud bin Abdulaziz University for Health Sciences (KSAU-HS); K,Alahsa,Saudi Arabia; King Abdulaziz Hospital, King Abdulaziz Medical City (KAMC) Ministry of National Guard Health Affairs (NGHA), Al Ahsa, Saudi Arabia,al ahsa,Saudi Arabia, Saudi Arabia
1 shared publication - Abdulmohsen AlMusaad
King Abdulaziz Medical City -National Guard Health Affairs, Riyadh, Saudi Arabia
1 shared publication - Abdulrahman A Alarfaj1 shared publication
- Gousay Alkhazmari
Prince Sultan Cardiac Center Al-Ahsa, Al-Ahsa, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 9 August 2024
- Published by MDPI AG in Preprints.org
Genotype-Phenotype Correlations in Inherited Cardiomyopathies, Their Role in Clinical Decision-Making and Implications in Personalized Cardiac Medicine in Multi-omics as Well as Disease Modelling Eras
Inherited cardiomyopathies are a diverse group of heart muscle diseases caused by genetic mutations that result in structural and functional abnormalities of the myocardium. Understanding genotype-phenotype correlations in these conditions is vital for personalized cardiac medicine, enabling targeted therapeutic strategies and predictive diagnostics. This review explores the major types of inherited cardiomyopathies—hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM)—and provides detailed insights into how different genetic mutations manifest as clinical features. The integration of multi-omics approaches and advanced disease modeling techniques has enhanced our ability to dissect these correlations. The review also discusses the implications of these findings for personalized medicine, including tailored therapeutic strategies, predictive diagnostics, and future research directions.
- 9 August 2024
- Published by MDPI AG in Preprints.org
Open AccessGenotype-Phenotype Correlations in Inherited Cardiomyopathies, Their Role in Clinical Decision-Making and Implications in Personalized Cardiac Medicine in Multi-omics as Well as Disease Modelling Eras
Inherited cardiomyopathies are a diverse group of heart muscle diseases caused by genetic mutations that result in structural and functional abnormalities of the myocardium. Understanding genotype-phenotype correlations in these conditions is vital for personalized cardiac medicine, enabling targeted therapeutic strategies and predictive diagnostics. This review explores the major types of inherited cardiomyopathies—hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive cardiomyopathy (RCM)—and provides detailed insights into how different genetic mutations manifest as clinical features. The integration of multi-omics approaches and advanced disease modeling techniques has enhanced our ability to dissect these correlations. The review also discusses the implications of these findings for personalized medicine, including tailored therapeutic strategies, predictive diagnostics, and future research directions.
- Open Access
- 20 December 2023
- Published by MDPI AG in Preprints.org
An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.
- 20 December 2023
- Published by MDPI AG in Preprints.org
Open AccessAn In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies
Background: COVID-19 was initially identified as a respiratory system disorder, but it has been discovered to interact with and influence the cardiovascular system. COVID-19-associated cardiovascular (CV) complications are common, resulting in high acute phase mortality and a large number of morbidities in the chronic phase, thus severely impacting patients' quality of life and health outcomes. Nevertheless, clinical, cellular, and molecular biological factors underlying the pathophysiology of cardiovascular complications associated with COVID-19 are poorly understood. Objective: This review investigates putative underlying clinical factors as well as cellular and molecular biological mechanisms by which COVID-19 leads to acute CV complications, including state-of-the-art genomic sequencing-based findings, assessing the long-term CV consequences of COVID-19, and aiming to shed light on developing strategies for differential diagnosis, risk prognostic stratification, prevention, and clinical management of CV sequlea in COVID-19 patients. Methods: For this purpose, a through review of literature and published data was carried out from first report of COVID-19 till October 2023 to find out a comprehensive account of clinical, cellular and molecular genetic factors underlying COVID-19-associated cardiovascular diseases. Results: We found that the relationship between COVID-19 and CV risk is complex and multifaceted. In addition to acute COVID-19 detertriuos effects, COVID-19 survivors may experience long-term CV effects. We provide a detailed account of the involvement of a large number of genomic alterations, microRNAs, and novel viral as well as host proteins in CVDs associated with COVID-19, which has helped identify some novel drug targets to treat COVID-19-related cardiovascular complications. Conclusions: The relationship between COVID-19 and CV risk is complex and multifaceted. While COVID-19 primarily affects the respiratory system, it can also significantly affect CV health. as compared to classical cardiovascular diseases, there are new clinical, cellular and molecular biological factors in CVDs related to COVID-19, that need specific diagnostic assays, prognostic stratification and treatment modules. Therefore, specail care is must taken to treat cardiovascular diseases associated with COVID-19.